Ignite Creation Date:
2024-05-06 @ 5:49 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05441956
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-10
First Post:
2022-06-23
Brief Title:
TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer NSCLC
Sponsor:
Shenzhen TargetRx Inc
Organization:
Shenzhen TargetRx Inc
Study Overview
Official Title:
A Dose Escalation and Expansion Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of TGRX-326 Monotherapy for the Treatment of Advanced ALK-positive or ROS1-positive Non-Small Cell Lung Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a multi-center single-arm open-label Phase I clinical trial in 3 phases dose escalation phase dose expansion phase and indication expansion phase which will explore the safety tolerability PK and preliminary efficacy of TGRX-326 in patients with ALK-positive or ROS1-positive advanced NSCLC
Detailed Description:
This is the first-in-human trial with TGRX-326 which aims to evaluate the safety profile and preliminary efficacy profile in patients with ALK-positive or ROS1-positive advanced NSCLC The primary purpose of this study is to evaluate the safety profile of TGRX-326 including determination of the maximal tolerated dose MTD and recommended phase II dose RP2D and other safety measures of the investigational drug such as adverse events and abnormal clinical outcomes Preliminary efficacy profiles of TGRX-326 is also evaluated according to RECIST Version 11 The safety tolerability and efficacy profiles along with pharmacokinetic analysis will be assessed together to determine the optimal dose for expansion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None